ZIOPHARM Oncology, Inc.
ZIOP shares are up more than 14 percent Tuesday morning following results from the Phase 3 (PICASSO 3) trial of
palifosfamide (ZIO-201) in first-line metastatic soft tissue sarcoma which
reached its target number of progression-free survival (PFS) events. PICASSO 3
is an international, randomized, double-blind, placebo-controlled trial whose
primary endpoint is PFS. According to the protocol and statistical plan,
reaching the target number of PFS events leads to completion of the blinded
data collection process and then formal efficacy analysis by the IDMC
(Independent Data Monitoring Committee). The Company will announce topline
results from this trial during the last week of March 2013.
"Reaching the target number of progression events for PICASSO 3 positions us
one step closer to understanding palifosfamide's full potential for this
significant unmet medical need," said Jonathan Lewis, M.D., Ph.D., Chief
Executive Officer of ZIOPHARM. "With a positive study outcome, palifosfamide
has the potential to become the first new treatment option in nearly 30 years
for patients with first-line metastatic soft tissue sarcoma."
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in